Young Americans' Marijuana Use Increases with Legalization: Survey

Nov.29.2022
Young Americans' Marijuana Use Increases with Legalization: Survey
Legalization of marijuana in the US has led to a significant increase in young adults smoking, according to a new survey.

A recent survey conducted in the United States has revealed a sharp increase in the number of young people consuming marijuana, following its legalization in many parts of the country, including New York.


A Gallup Poll analysis has revealed that 26% of individuals aged 18 to 29 have used marijuana, compared to 17% in 2015.


According to a Gallup report, smoking rates among young people have dropped from 35% in 2003 to 25% a decade ago, and now stand at 12%, which is more than two times lower than before.


According to an analysis by Gallup, smoking rates have dramatically declined in the past 20 years, driven mainly by a decrease in smoking among young people, which is encouraging for public health officials. However, more young people are turning to marijuana, possibly due to its legalization in more states and its prevalence among youth compared to traditional smoking, along with the use of e-cigarettes.


Twenty-one states have legalized the recreational use of marijuana, including several populous states on the East and West Coasts. Other states, such as Florida and Pennsylvania, have legalized marijuana for medicinal purposes.


According to Gallup's analysis, it supports a recent study published in the journal "Addictive Behaviors" by Temple University researchers. The study claims that "after the legalization of recreational marijuana use, the monthly usage rate among adolescents and young adults increased." The researchers warned that there will be an increase in marijuana addiction or untreated "marijuana use disorders.


The study also found that "among young adults, higher rates of marijuana use were associated with lower rates of hospitalization for CUD treatment.


Opponents of marijuana legalization say that their concerns are now in the past.


Due to coordinated preventative efforts, marijuana usage has steadily decreased for several decades. However, the legalization and commercialization of marijuana are now threatening to undo these public health benefits. "Smart Approaches to Marijuana" President Kevin Sabet stated, "We also cannot ignore the fact that young people are starting to use new forms of marijuana, such as e-cigarettes and concentrated products, which are closely linked to severe mental health risks and higher rates of addiction.


However, supporters say that they are pleased that people can use it legally.


I am delighted to be a part of this process. I am passionate about changing the stigma around cannabis. There is a certain stigma, but culture is changing," said Nicholas Koury, who last week received one of the first licenses issued by the state of New York to open a cannabis dispensary in Manhattan. "The stigma is not necessarily accurate. Cannabis can help people's mental state and has medicinal value," he said.


According to a survey, 26% of people aged 18 to 29 have admitted to using marijuana, which is higher than the reported 17% in 2015.


Last week, New York issued its first round of 28 cannabis dispensary licenses and is now tackling a rapidly growing unlicensed and unregulated black market where Budagges and other top shops openly sell marijuana and cannabis edibles.


According to a Gallup survey, some young smokers appear to be turning to e-cigarettes or less toxic electronic cigarettes, with approximately 7% of US adults reporting using them in the past week.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Holdings said the U.S. Food and Drug Administration notified the company on June 23, 2026, that 30 PACHA vape SKUs with submitted PMTAs had been tentatively identified for inclusion on a planned public-facing FDA webpage. Under enforcement guidance issued by FDA in May, the webpage is intended to identify certain unauthorized products for which the agency generally does not intend to prioritize enforcement of premarket authorization requirements. Charlie’s disclosed the development alongside second-quarter revenue of $3.8 million, up 116% year over year.
Aug.25
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
Australian Coalition Unveils Illicit Tobacco Plan With 80% Excise Cut and Legal, Taxed Vapes and Nicotine Pouches
Australian Coalition Unveils Illicit Tobacco Plan With 80% Excise Cut and Legal, Taxed Vapes and Nicotine Pouches
Australia’s Coalition has unveiled a national illicit-tobacco policy that would cut tobacco excise by 80% and create legal, regulated and taxed adult markets for vaping products and nicotine pouches if it wins government. The plan proposes an excise of A$0.50 per millilitre of e-liquid and A$0.025 per milligram of nicotine in pouches, alongside A$200 million in additional enforcement and a A$60 million three-year public-awareness campaign. The Coalition says the package would narrow the price advantage of illicit products and undermine organised crime, while Labor and public-health groups warn that dramatically cheaper cigarettes could reverse long-term declines in smoking.
Sep.03
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Ahead of implementation, DOJO, PIXL and Hayati have introduced or been reported to be adding lower-capacity tiers alongside larger products. DOJO has added a 6ml BLAST7K Fresh below its 10ml BLAST10K Fresh, PIXL offers both a 12ml 8000 and a 6ml 5K, while retailer Ninja Vapes says Hayati is preparing a 7ml 4K alongside its existing 12ml 6K. The pattern points to a growing lower-capacity tier in the UK market, although the brands have not all explicitly linked the changes to the new duty.
Sep.23
Product | IVG Launches NEXiO Prefilled Pod System, Expanding Beyond Disposable Vapes
Product | IVG Launches NEXiO Prefilled Pod System, Expanding Beyond Disposable Vapes
UK vape brand IVG has launched the NEXiO reusable prefilled pod system, expanding its product portfolio beyond disposable vape products. The device features a 1,000mAh rechargeable battery, prefilled pods with a refill reservoir structure and a claimed capacity of up to 10,000 puffs. Officially launched in the UK on July 9, 2026, NEXiO debuted with 17 flavor options, reflecting IVG’s move into reusable pod formats.
Aug.19
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28